Markt geöffnet· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half. CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline. That includes trials for alcohol use disorder and addiction treatments. hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials. The CEO says it opens up new markets and cross-selling opportunities in Germany. Gelion PLC (AIM:GELN, OTC:G
Chesnara PLC (LSE:CSN) CEO Steve Murray spoke with Proactive about first-half performance, including a 79% rise in operating capital generation to £96 million, progress integrating Chesnara Life and the outlook for further acquisitions. Murray said the strong capital generation reflected positive underlying performance, management actions like balance-sheet optimisation and reinsurance, and a significant contribution from Chesnara Life, formerly HSBC Life UK, which joined the group at the end of January. On integration, Murray said Chesnara has announced a combined UK leadership team and begun
Chesnara (LON:CSN) reported higher operating capital generation, cash remittances and adjusted operating profit for the first half of 2026, supported by the January acquisition of HSBC Life UK, now renamed Chesnara Life UK. Group Chief Executive Steve Murray said the company delivered “another very
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.